## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

#### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2006

PEDIATRIX MEDICAL GROUP, INC. (Exact name of registrant as specified in its charter)

Florida 001-12111 65-0271219 (State or other jurisdiction Commission File (IRS Employer of incorporation) Number Identification No.) 1301 Concord Terrace Sunrise, FL 33323

Sunrise, FL33323(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (954) 384-0175

N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 $|\_|$  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|\_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

 $|\_|$  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

\_ \_\_\_\_\_

Item 2.02. Results of Operations and Financial Condition.

On May 3, 2006, Pediatrix Medical Group, Inc. (the "Company") issued a press release announcing its results of operations for the three months ended March 31, 2006 (the "Release"). A copy of the Release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" with the Securities and Exchange Commission nor incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Item 9.01(a) Financial Statements of businesses acquired:

Not applicable.

Item 9.01(b) Pro Forma Financial Information:

Not applicable.

99.1 Press Release of Pediatrix Medical Group, Inc. dated May 3, 2006.

# SIGNATURES

Pursuant of the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PEDIATRIX MEDICAL GROUP, INC. (Registrant)

Date: May 3, 2006

By: /s/ Karl B. Wagner

Karl B. Wagner Chief Financial Officer

# Pediatrix Reports Non-GAAP Post-Split EPS of 55 Cents; Operating Efficiencies Drive Adjusted Net Income Growth of 24 Percent

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 3, 2006--Pediatrix Medical Group, Inc. (NYSE:PDX), today reported that it earned 55 cents per share for the three months ended March 31, 2006, as presented on a non-GAAP basis that excludes the impact of equity-based compensation expense, or 49 cents per share on a GAAP basis when including the impact of those expenses.

Pediatrix's 2006 first quarter earnings per share reflect the impact of a two-for-one stock split that was effective April 28, 2006.

Pediatrix's results for the 2006 first quarter include:

- Record quarterly revenue of \$187.7 million;
- -- Same-unit revenue growth of 6.9 percent, which included neonatal intensive care unit (NICU) patient volume growth of 4.3 percent;
- -- The investment of \$63.3 million to acquire physician group practices;
- Effective management of general and administrative expenses resulting in non-GAAP operating margin expansion of 130 basis points.

"This is another solid quarter for Pediatrix, one in which our strong revenue growth is exceeded by growth of operating income," said Roger J. Medel, M.D., Chief Executive Officer of Pediatrix. "These results were at the high end of our guided range for the quarter after considering the impact of our stock split. We continue to demonstrate that as we execute our growth strategy we remain focused on opportunities to manage our national group practice more efficiently."

Net patient service revenue increased by 14 percent for the three months ended March 31, 2006, to \$187.7 million, when compared to the same period of 2005. Revenue growth included contributions from acquisitions completed during the past year, as well as same-unit revenue growth of 6.9 percent. NICU patient volume increased by 4.3 percent for the 2006 first quarter, compared with the 2005 first quarter.

Income from operations was \$37.8 million for the three months ended March 31, 2006, as compared with \$29.3 million for the same period in 2005. When adjusted to exclude equity-based compensation expense, income from operations was \$42.8 million for the 2006 first quarter, up 21 percent from \$35.3 million for the 2005 first quarter after adjusting for a charge related to the national Medicaid and TRICARE investigation that was recorded in that period. General and administrative expenses, when adjusted for those same items, were 12.4 percent of revenue for the 2006 first quarter, down from 13.5 percent for the 2005 first quarter.

Operating margin was 20.1 percent for the three months ended March 31, 2006, up from 17.9 percent for the comparable 2005 period. On a non-GAAP basis, operating margin adjusted to exclude equity-based compensation expense was 22.8 percent for the 2006 first quarter, an increase of 130 basis points from the comparable period of 2005, after adjusting to exclude the charge related to the Medicaid investigation.

Net income for the three months ended March 31, 2006, was \$23.7 million, or 49 cents per share based on a weighted average 48.8 million shares outstanding, which compares with net income of \$18.0 million, or 38 cents per share, based on a weighted average 46.9 million shares outstanding for the three months ended March 31, 2005. When adjusted to exclude equity-based compensation, net income was \$26.9 million or 55 cents per share for 2006 first quarter, compared with \$21.7 million or 46 cents per share for the 2005 first quarter after adjusting to exclude the charge related to the Medicaid investigation.

At March 31, 2006, Pediatrix had cash and cash equivalents of \$4.5 million and net accounts receivable of \$115.8 million. Days sales outstanding remain less than 60.

Total debt of \$42.2 million at March 31, 2006, includes an outstanding balance of \$41 million under Pediatrix's \$225 million revolving credit facility.

Pediatrix used \$63.3 million of its cash and amounts available under its revolving credit facility to acquire physician group practices, including a neonatal group practice based in Atlanta, Georgia, and a pediatric cardiology physician group practice based in Springfield, Missouri.

Cash flow used in operations for the three months ended March 31,

2006, was \$11.2 million. Pediatrix normally experiences significant cash outflows during the first quarter of each year, principally because of annual bonus payments that are made to physicians under incentive programs for the prior year.

Reconciliation of Non-GAAP Information

Beginning with the first quarter of 2006, Pediatrix adopted Financial Accounting Standards No. 123R, "Share-Based Payments". This press release contains non-GAAP information for the three months ended March 31, 2006, that includes income from operations, operating margin, net income and earnings per share as adjusted to exclude equity-based compensation expense.

In addition, this press release contains non-GAAP information for the three months ended March 31, 2005, that includes income from operations, operating margin, net income and earnings per share as adjusted to exclude expenses related to a pre-tax charge as a result of an increase of the estimated liability relating to the Medicaid and TRICARE investigation.

Pediatrix believes that the presentation of non-GAAP information provides useful guidance to management and investors regarding financial and business trends related to its results of operations and that when non-GAAP information is viewed with GAAP information, investors are provided with a meaningful understanding of Pediatrix's ongoing operating financial performance. This information is not intended to be considered in isolation, or as a substitute for GAAP financial information. The following tables reconcile non-GAAP financial information to income from operations, net income and net income per common share which Pediatrix believes are the most comparable GAAP measures:

# Three Months Ended March 31, 2006 GAAP Adjustments Adjusted (in thousands except per share data)

Net patient service revenue	\$187,679	-	\$187,679
Operating expenses: Practice salaries and benefits Practice supplies and other operating expenses	112,483 7,802	(1,083)	111,400 7,802
General and administrative expenses Depreciation and amortization	27,238 2,348	(3,934)	23,304 2,348
Total operating expenses	149,871		144,854
Income from operations	37,808	-	42,825
Investment income Interest expense	450 (409)		450 (409)
Income before income taxes Income tax provision	37,849 (14,099)	1,869	42,866 (15,968)
Net income	\$23,750	-	\$26,898
Net income per common and common equivalent share (diluted)	\$0,49	\$0,06	\$0.55
Weighted average shares used in computing net income per common and common equivalent share (diluted)	48,844	<b>40100</b>	48,844
(4114004)	-0,0		-0,0-4

Share and per-share data for all periods presented have been adjusted to give effect to the two-for-one stock split that was effective April 28, 2006.

# Three Months Ended March 31, 2005 GAAP Adjustments Adjusted (in thousands except per share data)

Net patient service revenue	\$164,150	\$164,150
Operating expenses:		
Practice salaries and benefits	97,803	97,803

Practice supplies and other operating expenses General and administrative	6,250		6,250
expenses Depreciation and amortization	28,129 2,647	(6,000)	22,129 2,647
Total operating expenses	134,829		128,829
Income from operations	29,321		35,321
Investment income Interest expense	177 (840)		177 (840)
Income before income taxes Income tax provision	28,658 (10,675)	2,235	34,658 (12,910)
Net income	\$17,983		\$21,748
Net income per common and common equivalent share (diluted) Weighted average shares used in computing net income per common	\$0.38	\$0.08	\$0.46
and common equivalent share (diluted)	46,910		46,910

Share and per-share data for all periods presented have been adjusted to give effect to the two-for-one stock split that was effective April 28, 2006.

## Earnings conference call

Pediatrix Medical Group, Inc. will host an investor conference call to discuss the quarterly results at 11 a.m. (EDT) today. The conference call Webcast may be accessed from the Company's Website, http://www.pediatrix.com. A telephone replay of the conference call will be available from 1 p.m. (EDT) today through midnight (EDT) May 10, 2006 by dialing 800-475-6701, access code 824325. The replay will also be available at http://www.pediatrix.com.

#### About Pediatrix

Pediatrix Medical Group, Inc. is the nation's leading provider of newborn, maternal-fetal and pediatric physician subspecialty services. Pediatrix physicians and advanced nurse practitioners are reshaping the delivery of maternal-fetal and newborn care by identifying best demonstrated processes and participating in clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Founded in 1979, its neonatal physicians provide services at more than 240 NICUs, and through Obstetrix, its perinatal physicians provide services in many markets where Pediatrix's neonatal physicians practice. Combined, Pediatrix and its affiliated professional corporations employ more than 860 physicians in 32 states and Puerto Rico. Pediatrix is also the nation's largest provider of newborn hearing screens and newborn metabolic screening. Additional information is available at http://www.pediatrix.com.

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe", "hope", "may", "anticipate", "should", "intend", "plan", "will", "expect", "estimate", "project", "positioned", "strategy" and similar expressions, and are based on assumptions and assessments made by Pediatrix's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Pediatrix's most recent Annual Report on Form 10-K, including the section entitled

Pediatrix Medical Group, Consolidated Statements of (Unaudited)					
		Three months ended March 31, 2006 2005			
	(in	(in thousands, except per share data)			
Net patient service revenue	\$	187,679 \$	164,150		
Operating expenses: Practice salaries and benefits Practice supplies and other operating		112,483	97,803		
expenses General and administrative expenses Depreciation and amortization		7,802 27,238 2,348	28,129 2,647		
Total operating expenses		149,871	134,829		
Income from operations		37,808	29,321		
Investment income Interest expense		450 (409)	177 (840)		
Income before income taxes Income tax provision		37,849 (14,099)	28,658 (10,675)		
Net income		23,750 \$ ====================================			
Per share data: Net income per common and common equivalent share (diluted)	\$	0.49 \$	0.38		
Weighted average shares used in computing net income per common and common equivalent share (diluted)		48,844	46,910		

Share and per-share data for all periods presented have been adjusted to give effect to the two-for-one stock split that was effective April 28, 2006.

# Balance Sheet Highlights (Unaudited)

		As of 31, 2006		
	(in thousands)			
Assets: Cash and cash equivalents Short-term investments Accounts receivable, net Other current assets Other assets, property and equipment	\$	4,507 9,958 115,759 31,236 801,557		10,920 111,725 30,787
Total assets	\$ ===:	963,017 ======	\$ ====	900,403
Liabilities and shareholders' equity: Accounts payable & accrued expenses Total debt Other liabilities	\$	122,169 42,179 47,943		164,749 1,504 42,359
Total liabilities Shareholders' equity		212,291 750,726		208,612 691,791
Total liabilities and shareholders' equity	\$	963,017	\$	900,403

CONTACT: Pediatrix Medical Group, Inc., Fort Lauderdale Bob Kneeley, 954-384-0175, x-5300 bob\_kneeley@pediatrix.com